Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
10 Jun, 2019 (Monday)



AK MEDICAL(1789)
Analysis:
AK is mainly engaged in design, develop, produce and market orthopedic joint implants and related products, mainly through Beijing AKEC Medical. The company reported 2018 revenue of RMB600.6mn (+61.1% YoY) and net profit of RMB145mn (+37.5% YoY). Growth was mainly due to sales hike of by 3D-printed products, where the revenue grew from RMB33.4mn to RMB70mn, up by 109.1%. The revenue of Hip replacement implants Knee replacement implants increased by 63.5% and 42.7% respectively. China`s orthopedic joint implant market and spine replacement implant market are projected to further grow to RMB7.8 billion and RMB5.1 billion in terms of revenue, respectively, in 2021, representing a CAGR of 13.7% and 9.5%, respectively, between 2016 and 2021. AK Medical as the bestselling domestic orthopedic joint implant brand, is expected to continue fast growth in future.
Strategy:
Buy-in Price: $3.80, Target Price: $5.30, Cut Loss Price: $3.20


Chugai Pharmaceutical Co., Ltd. (4519.JT)
Chugai Pharmaceutical Co., Ltd. was founded in 1925 and company was established in 1943. In 2002, company became a subsidiary of the Swiss Roche group. Carries out the research, development, manufacture, retail and import and export of pharmaceuticals. It is the leading company domestically for biomedicine and antibody drugs, and holds the top shares for domestic sales of antibody drugs and in the cancer area. It has acquired certification for biomedicine in 116 countries. For FY2019/12 results for 1Q (Jan-Mar) announced on 24/4, sales revenue increased by 4.7% to 154.288 billion yen compared to the same period the previous year, operating income increased by 20.2% to 46.094 billion yen, and net income increased by 25.6% to 35.031 billion yen. TECENTRIQ, their new product in the cancer field, and main products such as PERJETA and ALECENSA are steady. Export of ALECENSA and ACTEMRA for Roche have grown. For the company's full year plan, sales revenue is expected to increase by 2.2% to 592.5 billion yen compared to the previous year, core operating income to increase by 9.7% to 143 billion yen, and core EPS to increase by 12.2% to 198 yen, with payout ratio at 48.5%. On 21/5, company announced the investment of 127.3 billion yen to build a research facility in Yokohama City. Company is consolidating their research function spread into 2 bases and is pursuing synergy effect. Recommend to buy at ¥7110, target price ¥7900, cut loss if drop below ¥6720.



CRSC (3969.HK) - Investment in infrastructure projects rebounded in 2019; listing in STI board could be a catalyst

Investment Summary

CRSC is a leader in the global rail transportation control system market, which mainly engaged in design and integration, equipment manufacturing and system implementation of rail transportation control systems. It is the only rail transportation control system solution provider in the world, which is capable of independently providing the entire suite of products and services with competitive advantages across the whole industry value chain. We derived a TP of HK$6.64, and upgraded to a “Buy” rating due to the recent drop in share price, with a potential upside of 29.7%.(Closing price at 4 Jun 2019)

Remarkable growth in revenue and external contracts, while GPM dropped

On Mar 20, The Group released its 2018 annual result, which the revenue grew by 15.7% to RMB 39.84 bn, whereas the net profit just rose by 8% to RMB 3.8 bn. During the period, the GPM dropped by 2%, due to the increasing proportion of the business which has a lower GPM; the NPM also reduced by 0.7% to 9.5%. In 2018, the total aggregate amount of external contracts signed by the Group was RMB 68.29 bn, representing an increase of 12.4% over the same period in 2017. The total amount of external contracts signed in Railway, Urban Transit, and Subway were RMB25.08, 11.61 and 11.6 bn respectively. The amount in the General Construction Contracting Business and Other Businesses was RMB 29.85 bn.

Besides, the Group also released the total aggregate amount of external contracts signed for the first quarter. As of 31 Mar 2019, the total aggregate amount of external contracts signed was RMB 7.48 bn, up by 16.1% YoY, in which the amount of external contracts signed in Railway was RMB 3.98 bn, up by 22.5% YoY; the amount in Urban Transit was RMB 1.86 bn, increased by 14.4%; the amount in the Oversea Business was RMB 130 mn, rose sharply by 282.4% YoY; the amount in the General Construction Contracting Business and Other Businesses was RMB 1.52 bn, down by 1.4%

Investment in infrastructure projects rebounded in 2019

Since the government has vigorously promoted de-leveraging in 2018, making local governments difficult to finance, fixed assets investment in transportation, warehousing and postal services has only increased by 4.4% in 2018 and 7.2% YoY in October-December. The Group also indicated that many projects have been suspended. However, as China-US trade conflicts heat up, the uncertainty in China's economic growth rises. At the meeting, the Politburo of the Communist Party of China proposed “Six stables” (Stable employment, Stable finance, Stable foreign trade, Stable foreign investment, Stable investment, Stable expectations).

Among them, "Stable investment" is regarded as an incentive for investment in fixed assets, because in the past when the economic growth slowed down, the investment in fixed assets was used as a countermeasure. In February this year, the National Development and Reform Commission released the 񓠂 National Fixed Assets Investment Development Trend Monitoring Report and the 2019 Investment Situation Outlook", indicating that infrastructure investment is expected to maintain a medium-speed growth in 2019. We believe that infrastructure projects such as transportation will be rebounded in 2019 to offset the impact from foreign trade.

Listing in Science and technology innovation board could become a valuation catalyst

The Group plans to issue A shares on the Science and Technology Board and has been accepted by the Shanghai Stock Exchange. The Group plans to issue no more than 2.197 billion new A shares, and the net proceeds are estimated to be RMB 10.5 bn. It will be used for advanced and intelligent technology research and development projects (including advanced rail transit control systems and key technology research, rail transit intelligent integrated operation and maintenance). System and technology research, smart city and industry communication information system research, etc.), advanced and intelligent manufacturing base projects and supplementary liquidity. As the average valuation of the A-share market is higher than that of the Hong Kong stock market, we expect the Group's valuation in STI Board to be higher than the current Hong Kong market, and could drive up the valuation in Hong Kong market in the future.

Valuation

Based on a P/E ratio of 12.5x (the average of the past forward P/E), we derived a TP of HK$6.64, implying a P/E of 10.6x in 2020F. Due to the recent drop in share price, we upgraded to a “Buy” rating , with a potential upside of 29.7%. (HKD/CNY=0.889)

Risk

1. Growth of railway investment fails to meet expectations

2. Fierce competition in urban rail market leads to bidding failure

3. Profitability level fails to meet expectations

Financials

Click Here for PDF format...




Recommendation on 10-6-2019
RecommendationBuy
Price on Recommendation Date$ 5.120
Suggested purchase priceN/A
Target Price$ 6.640
Writer Info
Terry Li
(Research Analyst)
Tel: +852 2277 6527
Email:
terryli@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.